GENE ONLINE|News &
Opinion
Blog

2025-12-01|

CMS to End Kidney Failure Payment Model Two Years Early After Failing to Improve Outcomes or Reduce Costs

by GOAI
Share To

The Centers for Medicare and Medicaid Services (CMS) has announced the early termination of a payment model designed to address kidney failure. Initially scheduled to run through 2027, the program will now conclude in 2025, two years ahead of its planned end date. The decision follows an evaluation that found the initiative did not achieve its intended goals of improving care outcomes or reducing costs for patients with kidney failure.

The experimental payment model aimed to incentivize better care coordination and encourage home dialysis use by altering reimbursement structures for providers. However, CMS determined that the trial failed to demonstrate significant improvements in patient outcomes or cost savings during its implementation period. This marks a notable shift in federal efforts to reform dialysis care, as kidney disease remains a critical public health issue affecting millions of Americans annually. Further details on how CMS plans to address these challenges moving forward have not yet been disclosed.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top